{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T21:16:55Z","timestamp":1792185415435,"version":"4.4.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T00:00:00Z","timestamp":1728432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T00:00:00Z","timestamp":1728432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Positron emission tomography (PET) stands as the paramount clinical molecular imaging modality, especially in oncology. Unlike conventional anatomical-morphological imaging methods such as computed tomography (CT) and magnetic resonance imaging (MRI), PET provides detailed visualizations of internal activity at the molecular and cellular levels.<\/jats:p>\n                    <jats:p>\n                      18-fluorine-fluorodeoxyglucose ([\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG)-PET combined with contrast-enhanced CT (ceCT) significantly improves the detection of various cancers. Appropriate patient selection is crucial, and physicians should carefully assess the appropriateness of [\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG-PET\/CT based on specific clinical criteria and evidence. Due to its high diagnostic accuracy, [\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG-PET\/CT is indispensable for evaluating the extent of disease, staging, and restaging known malignancies, and assessing the response to therapy. PET\/CT imaging offers significant advantages in patient management, particularly by identifying occult metastases that might otherwise go undetected. This can help prevent unnecessary surgeries, allowing many patients to be redirected to systemic chemotherapy instead. However, it is important to note that the gold standard for surgical planning remains CT and\/or MRI, depending on the body region. These imaging modalities, with or without associated angiography, provide superior contrast and spatial resolution, essential for detailed surgical preparation and planning.\n                    <\/jats:p>\n                    <jats:p>\n                      [\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG-PET\/CT has a central role in the precise and early diagnosis of cancer, contributing significantly to personalized treatment plans. However, it has limitations, including non-tumor-specific uptake and the potential to inaccurately capture the metabolic activity of certain tumor types due to low uptake in some well-differentiated tumor cell lines. Therefore, it should be utilized in clinical scenarios where it offers crucial diagnostic insights not readily available with other imaging modalities.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key Points<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>\n                            <jats:italic>Use [<\/jats:italic>\n                            <jats:sup>\n                              <jats:italic>18<\/jats:italic>\n                            <\/jats:sup>\n                            <jats:italic>F]FDG-PET\/CT selectively based on clinical appropriateness criteria and existing evidence to optimize resource utilization and minimize patient exposure<\/jats:italic>\n                            .\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            <jats:italic>Employ [<\/jats:italic>\n                            <jats:sup>\n                              <jats:italic>18<\/jats:italic>\n                            <\/jats:sup>\n                            <jats:italic>F]FDG-PET\/CT in treatment planning and monitoring, particularly for assessing chemotherapy or radiotherapy response in FDG-avid lymphoma and solid tumors<\/jats:italic>\n                            .\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            <jats:italic>When available, [<\/jats:italic>\n                            <jats:sup>\n                              <jats:italic>18<\/jats:italic>\n                            <\/jats:sup>\n                            <jats:italic>F]FDG-PET\/CT can be integrated with other diagnostic tools, such as MRI, to enhance overall diagnostic accuracy<\/jats:italic>\n                            .\n                          <\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00330-024-11094-8","type":"journal-article","created":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T13:02:40Z","timestamp":1728478960000},"page":"1894-1902","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["ESR Essentials: staging and restaging with FDG-PET\/CT in oncology\u2014practice recommendations by the European Society for Hybrid, Molecular and Translational Imaging"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-0851-0094","authenticated-orcid":false,"given":"Ricarda","family":"Ebner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel T.","family":"Sheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Brendel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Ricke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens C.","family":"Cyran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,9]]},"reference":[{"key":"11094_CR1","doi-asserted-by":"publisher","first-page":"333","DOI":"10.3322\/caac.21713","volume":"72","author":"SP Rowe","year":"2022","unstructured":"Rowe SP, Pomper MG (2022) Molecular imaging in oncology: current impact and future directions. CA Cancer J Clin 72:333\u2013352","journal-title":"CA Cancer J Clin"},{"key":"11094_CR2","doi-asserted-by":"publisher","first-page":"368","DOI":"10.7861\/clinmedicine.12-4-368","volume":"12","author":"H Fahim Ul","year":"2012","unstructured":"Fahim Ul H, Cook GJ (2012) PET\/CT in oncology. Clin Med 12:368\u2013372","journal-title":"Clin Med"},{"key":"11094_CR3","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s00259-014-2885-5","volume":"42","author":"P Heusch","year":"2015","unstructured":"Heusch P, Nensa F, Schaarschmidt B et al (2015) Diagnostic accuracy of whole-body PET\/MRI and whole-body PET\/CT for TNM staging in oncology. Eur J Nucl Med Mol Imaging 42:42\u201348","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"11094_CR4","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJ et al (2015) FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging 42:328\u2013354","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"11094_CR5","doi-asserted-by":"publisher","first-page":"122s","DOI":"10.2967\/jnumed.108.057307","volume":"50","author":"RL Wahl","year":"2009","unstructured":"Wahl RL, Jacene H, Kasamon Y, Lodge MA (2009) From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 50:122s\u2013150s","journal-title":"J Nucl Med"},{"key":"11094_CR6","doi-asserted-by":"publisher","first-page":"617","DOI":"10.21037\/tlcr.2017.09.01","volume":"6","author":"BS Greenspan","year":"2017","unstructured":"Greenspan BS (2017) Role of PET\/CT for precision medicine in lung cancer: perspective of the Society of Nuclear Medicine and Molecular Imaging. Transl Lung Cancer Res 6:617\u2013620","journal-title":"Transl Lung Cancer Res"},{"key":"11094_CR7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1590\/0100-3984.2014.0012","volume":"49","author":"MP Mosmann","year":"2016","unstructured":"Mosmann MP, Borba MA, de Macedo FP, Liguori Ade A, Villarim Neto A, de Lima KC (2016) Solitary pulmonary nodule and 18F-FDG PET\/CT. Part 1: epidemiology, morphological evaluation and cancer probability. Radiol Bras 49:35\u201342","journal-title":"Radiol Bras"},{"key":"11094_CR8","doi-asserted-by":"publisher","first-page":"340","DOI":"10.6004\/jnccn.2023.0020","volume":"21","author":"DS Ettinger","year":"2023","unstructured":"Ettinger DS, Wood DE, Aisner DL et al (2023) NCCN Guidelines\u00ae Insights: Non\u2013small Cell Lung Cancer, Version 2.2023: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 21:340\u2013350","journal-title":"J Natl Compr Canc Netw"},{"key":"11094_CR9","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.6004\/jnccn.2021.0058","volume":"19","author":"AKP Ganti","year":"2021","unstructured":"Ganti AKP, Loo BW, Bassetti M et al (2021) Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 19:1441\u20131464","journal-title":"J Natl Compr Canc Netw"},{"key":"11094_CR10","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.6004\/jnccn.2023.0057","volume":"21","author":"AD Zelenetz","year":"2023","unstructured":"Zelenetz AD, Gordon LI, Abramson JS et al (2023) NCCN Guidelines\u00ae Insights: B-Cell Lymphomas, Version 6.2023. J Natl Compr Canc Netw 21:1118\u20131131","journal-title":"J Natl Compr Canc Netw"},{"key":"11094_CR11","doi-asserted-by":"publisher","first-page":"5941","DOI":"10.3390\/cancers14235941","volume":"14","author":"AE Salem","year":"2022","unstructured":"Salem AE, Shah HR, Covington MF et al (2022) PET-CT in clinical adult oncology: I. Hematologic malignancies. Cancers (Basel) 14:5941","journal-title":"Cancers"},{"key":"11094_CR12","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1182\/blood-2005-06-2252","volume":"107","author":"M Hutchings","year":"2006","unstructured":"Hutchings M, Loft A, Hansen M et al (2006) FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107:52\u201359","journal-title":"Blood"},{"key":"11094_CR13","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1097\/HS9.0000000000000005","volume":"1","author":"A Engert","year":"2017","unstructured":"Engert A, Goergen H, Markova J et al (2017) Reduced-intensity chemotherapy in patients with advanced-stage Hodgkin lymphoma: updated results of the open-label, international, randomised phase 3 HD15 trial by the German Hodgkin Study Group. Hemasphere 1:e5","journal-title":"Hemasphere"},{"key":"11094_CR14","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1016\/S0140-6736(17)32134-7","volume":"390","author":"P Borchmann","year":"2017","unstructured":"Borchmann P, Goergen H, Kobe C et al (2017) PET-guided treatment in patients with advanced-stage Hodgkin\u2019s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet 390:2790\u20132802","journal-title":"Lancet"},{"key":"11094_CR15","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.23.30301","volume":"222","author":"V Murad","year":"2024","unstructured":"Murad V, Kohan A, Ortega C, Prica A, Veit-Haibach P, Metser U (2024) Role of FDG PET\/CT in patients with lymphoma treated with chimeric antigen receptor T-cell therapy: current concepts. AJR Am J Roentgenol 222:e2330301","journal-title":"AJR Am J Roentgenol"},{"key":"11094_CR16","doi-asserted-by":"publisher","first-page":"153535082412579","DOI":"10.1177\/15353508241257924","volume":"23","author":"SB Singh","year":"2024","unstructured":"Singh SB, Bhandari S, Siwakoti S et al (2024) PET\/CT in the evaluation of CAR-T cell immunotherapy in hematological malignancies. Mol Imaging 23:15353508241257924","journal-title":"Mol Imaging"},{"key":"11094_CR17","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1097\/MLG.0b013e31805d017b","volume":"117","author":"AJ Fleming Jr","year":"2007","unstructured":"Fleming Jr AJ, Smith Jr SP, Paul CM et al (2007) Impact of [18F]-2-fluorodeoxyglucose-positron emission tomography\/computed tomography on previously untreated head and neck cancer patients. Laryngoscope 117:1173\u20131179","journal-title":"Laryngoscope"},{"key":"11094_CR18","doi-asserted-by":"publisher","first-page":"224","DOI":"10.6004\/jnccn.2022.0016","volume":"20","author":"JJ Caudell","year":"2022","unstructured":"Caudell JJ, Gillison ML, Maghami E et al (2022) NCCN Guidelines\u00ae Insights: Head and Neck Cancers, Version 1.2022. J Natl Compr Canc Netw 20:224\u2013234","journal-title":"J Natl Compr Canc Netw"},{"key":"11094_CR19","doi-asserted-by":"publisher","first-page":"63","DOI":"10.4103\/njcp.njcp_198_18","volume":"22","author":"K Kutluturk","year":"2019","unstructured":"Kutluturk K, Simsek A, Comak A, Gonultas F, Unal B, Kekilli E (2019) Factors affecting the accuracy of 18F-FDG PET\/CT in evaluating axillary metastases in invasive breast cancer. Niger J Clin Pract 22:63\u201368","journal-title":"Niger J Clin Pract"},{"key":"11094_CR20","doi-asserted-by":"publisher","first-page":"40","DOI":"10.4236\/ojmi.2013.31006","volume":"3","author":"K Taori","year":"2013","unstructured":"Taori K, Dhakate S, Rathod J et al (2013) Evaluation of breast masses using mammography and sonography as first line investigations. Open J Med Imaging 3:40\u201349","journal-title":"Open J Med Imaging"},{"key":"11094_CR21","doi-asserted-by":"publisher","first-page":"594","DOI":"10.6004\/jnccn.2023.0031","volume":"21","author":"WJ Gradishar","year":"2023","unstructured":"Gradishar WJ, Moran MS, Abraham J et al (2023) NCCN Guidelines\u00ae Insights: Breast Cancer, Version 4.2023. J Natl Compr Canc Netw 21:594\u2013608","journal-title":"J Natl Compr Canc Netw"},{"key":"11094_CR22","doi-asserted-by":"publisher","first-page":"254","DOI":"10.2214\/AJR.19.21177","volume":"213","author":"GA Ulaner","year":"2019","unstructured":"Ulaner GA (2019) PET\/CT for patients with breast cancer: where is the clinical impact? AJR Am J Roentgenol 213:254\u2013265","journal-title":"AJR Am J Roentgenol"},{"key":"11094_CR23","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.suronc.2013.03.001","volume":"22","author":"S Hong","year":"2013","unstructured":"Hong S, Li J, Wang S (2013) 18FDG PET-CT for diagnosis of distant metastases in breast cancer patients. A meta-analysis. Surg Oncol 22:139\u2013143","journal-title":"Surg Oncol"},{"key":"11094_CR24","first-page":"672","volume":"36","author":"Z Sun","year":"2015","unstructured":"Sun Z, Yi YL, Liu Y, Xiong JP, He CZ (2015) Comparison of whole-body PET\/PET-CT and conventional imaging procedures for distant metastasis staging in patients with breast cancer: a meta-analysis. Eur J Gynaecol Oncol 36:672\u2013676","journal-title":"Eur J Gynaecol Oncol"},{"key":"11094_CR25","first-page":"461","volume":"9","author":"R Piva","year":"2017","unstructured":"Piva R, Ticconi F, Ceriani V et al (2017) Comparative diagnostic accuracy of 18F-FDG PET\/CT for breast cancer recurrence. Breast Cancer 9:461\u2013471","journal-title":"Breast Cancer"},{"key":"11094_CR26","doi-asserted-by":"publisher","first-page":"808","DOI":"10.4251\/wjgo.v12.i8.808","volume":"12","author":"S Chakrabarti","year":"2020","unstructured":"Chakrabarti S, Peterson CY, Sriram D, Mahipal A (2020) Early stage colon cancer: current treatment standards, evolving paradigms, and future directions. World J Gastrointest Oncol 12:808\u2013832","journal-title":"World J Gastrointest Oncol"},{"key":"11094_CR27","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","volume":"34","author":"A Cervantes","year":"2023","unstructured":"Cervantes A, Adam R, Rosell\u00f3 S et al (2023) Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 34:10\u201332","journal-title":"Ann Oncol"},{"key":"11094_CR28","doi-asserted-by":"publisher","first-page":"329","DOI":"10.6004\/jnccn.2021.0012","volume":"19","author":"AB Benson","year":"2021","unstructured":"Benson AB, Venook AP, Al-Hawary MM et al (2021) Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 19:329\u2013359","journal-title":"J Natl Compr Canc Netw"},{"key":"11094_CR29","doi-asserted-by":"publisher","first-page":"1161738","DOI":"10.3389\/fonc.2023.1161738","volume":"13","author":"ML Schnitzer","year":"2023","unstructured":"Schnitzer ML, von M\u00fcnchhausen N, Biechele G et al (2023) Cost-effectiveness analysis of MRI, CE-CT and 18F-FDG PET\/CT for detecting colorectal liver metastases eligible for hepatic resection. Front Oncol 13:1161738","journal-title":"Front Oncol"},{"key":"11094_CR30","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1102\/1470-7330.2013.0005","volume":"13","author":"FC Gaertner","year":"2013","unstructured":"Gaertner FC, F\u00fcrst S, Schwaiger M (2013) PET\/MR: a paradigm shift. Cancer Imaging 13:36\u201352","journal-title":"Cancer Imaging"},{"key":"11094_CR31","doi-asserted-by":"publisher","first-page":"e220749","DOI":"10.1148\/radiol.220749","volume":"306","author":"Y Mori","year":"2023","unstructured":"Mori Y, Dendl K, Cardinale J, Kratochwil C, Giesel FL, Haberkorn U (2023) FAPI PET: fibroblast activation protein inhibitor use in oncologic and nononcologic disease. Radiology 306:e220749","journal-title":"Radiology"},{"key":"11094_CR32","doi-asserted-by":"crossref","unstructured":"Combes AD, Palma CA, Calopedos R et al (2022) PSMA PET-CT in the diagnosis and staging of prostate cancer. Diagnostics 12:2594","DOI":"10.3390\/diagnostics12112594"},{"key":"11094_CR33","doi-asserted-by":"publisher","first-page":"204","DOI":"10.2967\/jnumed.122.264860","volume":"64","author":"TA Hope","year":"2023","unstructured":"Hope TA, Allen-Auerbach M, Bodei L et al (2023) SNMMI procedure standard\/EANM practice guideline for SSTR PET: imaging neuroendocrine tumors. J Nucl Med 64:204\u2013210","journal-title":"J Nucl Med"},{"key":"11094_CR34","doi-asserted-by":"publisher","first-page":"e220143","DOI":"10.1148\/rg.220143","volume":"43","author":"SR O\u2019Brien","year":"2023","unstructured":"O\u2019Brien SR, Edmonds CE, Lanzo SM, Weeks JK, Mankoff DA, Pantel AR (2023) 18F-Fluoroestradiol: current applications and future directions. Radiographics 43:e220143","journal-title":"Radiographics"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-024-11094-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00330-024-11094-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-024-11094-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T05:28:28Z","timestamp":1742189308000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00330-024-11094-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,9]]},"references-count":34,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["11094"],"URL":"https:\/\/doi.org\/10.1007\/s00330-024-11094-8","relation":{},"ISSN":["1432-1084"],"issn-type":[{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,9]]},"assertion":[{"value":"15 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The scientific guarantor of this publication is C.C.C.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No complex statistical methods were necessary for this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statistics and biometry"}},{"value":"Written informed consent was obtained from all subjects (patients) in this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Institutional Review Board approval was not required.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Study subjects or cohorts overlap"}},{"order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Methodology"}}]}}